Total Payments
$56,494
2024 Payments
$45,218
Companies
42
Transactions
494
Medicare Patients
2,886
Medicare Billing
$725,824
Payment Breakdown by Category
Other$38,500 (68.1%)
Food & Beverage$11,728 (20.8%)
Travel$5,009 (8.9%)
Consulting$1,250 (2.2%)
Education$6.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,500 | 18 | 68.1% |
| Food and Beverage | $11,728 | 442 | 20.8% |
| Travel and Lodging | $5,009 | 32 | 8.9% |
| Consulting Fee | $1,250 | 1 | 2.2% |
| Education | $6.96 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | $42,280 | 66 | $0 (2024) |
| ABBVIE INC. | $2,223 | 131 | $0 (2024) |
| PFIZER INC. | $1,732 | 36 | $0 (2024) |
| Ardelyx, Inc. | $1,656 | 21 | $0 (2024) |
| Novo Nordisk AS | $1,460 | 4 | $0 (2017) |
| Allergan Inc. | $1,251 | 10 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,092 | 58 | $0 (2024) |
| Gilead Sciences, Inc. | $967.78 | 36 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $678.56 | 4 | $0 (2023) |
| Endogastric Solutions, Inc | $519.36 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,218 | 151 | Phathom Pharmaceuticals, Inc. ($42,280) |
| 2023 | $1,073 | 65 | AbbVie Inc. ($334.51) |
| 2022 | $1,107 | 59 | ABBVIE INC. ($244.69) |
| 2021 | $909.15 | 43 | AbbVie Inc. ($404.52) |
| 2020 | $674.25 | 39 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($249.40) |
| 2019 | $1,256 | 58 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($495.09) |
| 2018 | $3,912 | 42 | PFIZER INC. ($1,248) |
| 2017 | $2,345 | 37 | Novo Nordisk AS ($1,460) |
All Payment Transactions
494 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $153.22 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/17/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $117.37 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $98.42 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $22.51 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $15.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $4.79 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | Cash or cash equivalent | $33.66 | General |
| Category: Antibiotic | ||||||
| 11/07/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: LIVER DISEASE | ||||||
| 11/01/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/30/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/30/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/29/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: LIVER DISEASE | ||||||
| 10/25/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/25/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $138.06 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Gastroenterology | ||||||
| 10/24/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 983 | 34,358 | $1.1M | $419,578 |
| 2022 | 18 | 799 | 10,056 | $503,134 | $177,847 |
| 2021 | 16 | 679 | 798 | $261,615 | $80,891 |
| 2020 | 14 | 425 | 567 | $141,766 | $47,509 |
Total Patients
2,886
Total Services
45,779
Medicare Billing
$725,824
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 81 | 33,228 | $768,241 | $310,975 | 40.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 219 | $46,191 | $22,824 | 49.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 142 | 152 | $31,950 | $16,544 | 51.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 98 | 142 | $22,653 | $14,140 | 62.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 38 | 39 | $27,977 | $8,028 | 28.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 47 | $13,673 | $6,944 | 50.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $13,155 | $6,824 | 51.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 79 | 86 | $48,835 | $5,769 | 11.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 56 | 56 | $33,003 | $4,716 | 14.3% |
| 44361 | Biopsy of small bowel (except ileum) using an endoscope | Facility | 2023 | 44 | 45 | $11,273 | $4,112 | 36.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $7,446 | $3,891 | 52.3% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 17 | 19 | $5,963 | $3,146 | 52.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 46 | $5,106 | $3,049 | 59.7% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $9,197 | $2,621 | 28.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $7,218 | $2,042 | 28.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 88 | 136 | $3,115 | $1,696 | 54.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 16 | $2,311 | $1,184 | 51.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 18 | $1,080 | $744.12 | 68.9% |
| 43762 | Replacement of stomach stoma tube | Facility | 2023 | 11 | 11 | $2,383 | $330.66 | 13.9% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2022 | 24 | 9,088 | $274,247 | $86,066 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 172 | $36,108 | $18,154 | 50.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 121 | 198 | $21,976 | $11,918 | 54.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 49 | 49 | $36,749 | $9,866 | 26.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 103 | 110 | $17,117 | $9,279 | 54.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 49 | 50 | $10,510 | $5,694 | 54.2% |
About Dr. Brian Riff, MD
Dr. Brian Riff, MD is a Gastroenterology healthcare provider based in Anaheim, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1194969030.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Riff, MD has received a total of $56,494 in payments from pharmaceutical and medical device companies, with $45,218 received in 2024. These payments were reported across 494 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($38,500).
As a Medicare-enrolled provider, Riff has provided services to 2,886 Medicare beneficiaries, totaling 45,779 services with total Medicare billing of $725,824. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Anaheim, CA
- Active Since 04/22/2009
- Last Updated 04/17/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1194969030
Products in Payments
- VOQUEZNA (Drug) $42,280
- IBSRELA (Drug) $1,656
- Saxenda (Drug) $1,460
- XIFAXAN (Drug) $866.50
- ESOPHYX (Device) $519.36
- XELJANZ (Drug) $483.99
- Humira (Biological) $454.96
- RINVOQ (Biological) $413.67
- MAVYRET (Drug) $315.28
- SKYRIZI (Biological) $289.67
- HUMIRA (Biological) $203.28
- LINZESS (Drug) $197.41
- STELARA (Biological) $192.81
- DUPIXENT (Biological) $182.39
- TRULANCE (Drug) $142.82
- Cook Medical Biliary (Device) $139.87
- Da Vinci Surgical System (Device) $139.55
- Epclusa (Drug) $125.00
- Livdelzi (Drug) $118.34
- truFreeze (Device) $113.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Anaheim
Amit Bhanvadia, M.d, M.D
Gastroenterology — Payments: $21,110
Gastroenterology $21,110
Dick Yip, Md, MD
Gastroenterology — Payments: $19,278
Gastroenterology $19,278
Dr. Jason Yip, M.d, M.D
Gastroenterology — Payments: $5,925
Gastroenterology $5,925
Dr. Michael Kim, M.d, M.D
Gastroenterology — Payments: $5,642
Gastroenterology $5,642
Amber Garza
Gastroenterology — Payments: $2,397
Gastroenterology $2,397
Ravindra Alapati, Md, MD
Gastroenterology — Payments: $1,890
Gastroenterology $1,890